NEW YORK (GenomeWeb News) – Startup drug developer Constellation Pharmaceuticals will use BioTrove’s screening and analysis system to develop new therapeutics using an epigenetics-focused approach, BioTrove said today.
Constellation will use BioTrove’s RapidFire mass spectrometry system in its screening efforts aimed at developing drugs that can manipulate histone proteins to alter gene expression.
The RapidFire system feeds samples directly into a mass spectrometer at around six to eight seconds per sample, the company said, which streamlines screening and will help Constellation screen drug candidates more efficiently. BioTrove said the system can be used to analyze of range of targets, including triglycerides, lipids, fatty acids, neurotransmitters, anti-fungals, and others that the company called “difficult to study.”
Cambridge, Mass.-based Constellation was founded in April of this year and is funded with $32 million in Series A backing from Third Rock Ventures, the Column Group, and Venrock.
Constellation CEO Mark Levin said in a statement that the RapidFire system will help by “reducing our research and development time,” and by enhancing the company’s ability to identify new lead compounds for multiple therapeutic areas.
Financial terms of the agreement were not released.